---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-070230"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T13:05:55.419365+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics announces preclinical data on oral triagonist and updates on pipeline milestones

## Summary
- Preclinical study of incretin triagonist (GLP-1, GIP, glucagon) showed similar weight loss and lipid reduction via endoscope vs SC; no serious adverse events.
- RT-102 (teriparatide for osteoporosis) Phase 2 trial expected to start in 2024.
- Topline results from RT-111 Phase 1 (ustekinumab biosimilar) expected Q1 2024.
- RaniPill HC development expected ready for Phase 1 trials in H2 2024.

## SEC filing metadata
- accession: 0000950170-23-070230
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023070230/0000950170-23-070230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023070230/rani-20231214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-070230
- JSON: https://secwatch.observer/filing/0000950170-23-070230.json
- Plain text: https://secwatch.observer/filing/0000950170-23-070230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.